Corporate & Investor Presentation

Track record of strong financial returns for shareholders (Financial data as of December 31, 2021) $2.0 Revenue ($B) 12% CAGR $3.4 LTM 2Q17 LTM 2Q22 Non-GAAP Operating Income ($M) $490 16% CAGR $1,051 LTM 2017 LTM 2Q22 Non-GAAP EPS $2.78 15% CAGR $5.63 LTM 2Q17 LTM 2Q22 Total shareholder return, TSR (NYSE shares as of 12/31/2021): 1-yr 23% | 3-yr 135% | 5-yr 346% NOTE: See reconciliation to GAAP in Appendix 30 2022 ResMed | Corporate & Investor Presentation - updated 27JAN22 ResMed

View entire presentation